Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...
Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and ...
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...
Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...
Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of ...
Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of ...
German biosimilar manufacturer STADA Arzneimittel reported a 9% revenue increase in the first half of 2024, with over €2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback